Download Library

 
 
 
Download Library
Document Type
A Phase IIA Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients with Relapsed, Recurrent and / or Metastatic Cervical Cancer - ESMO presentation - September 2017 (Vergote)
PDF
626.4 KB
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer - ESMO abstract - August 2017 (Vergote)
URL
N/A
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors - ESMO abstract - August 2017 (Chenard-Poirier)
URL
N/A
Q2 2017 Results Podcast
MP3
24.9 MB
Interim Report for the First Half 2017
pdf
571.2 KB
Genmab First Half 2017 Results Presentation
PDF
157.1 KB
10th Kempen & Co. Life Science Conference - April 2017
PDF
1.5 MB
Development of a clinical trial immunohistochemistry assay using a novel antibody to CD38 - ASCO presentation - June 2017 (Wakamiya)
PDF
896.7 KB
First-in-human trial to evaluate safety of HuMax-Axl-ADC in patients with solid tumors - ASCO poster - June 2017 (Lassen)
PDF
2.7 MB
Daratumumab in combination with KRd in patients with newly diagnosed multiple myeloma (MMY1001) - ASCO presentation - June 2017 (Jakubowiak)
PDF
787.3 KB
Efficacy of DRd or DVd in RRMM based on cytogenetic risk status - ASCO presentation - June 2017 (Weisel)
PDF
754.8 KB
Development of a clinical trial immunohistochemistry assay using a novel antibody to CD38 - ASCO abstract - May 2017 (Wakamiya)
PDF
31.3 KB
DRd vs Rd in RRMM: Efficacy and safety update (POLLUX) -ASCO abstract - May 2017 (Bahlis)
PDF
89.7 KB
Phase Ib/II atezolizumab with or without daratumumab in previously treated advanced or metastatic NSCLC - ASCO abstract - May 2017 (Pillai)
PDF
81.7 KB
Daratumumab in combination with KRd in patients with newly diagnosed multiple myeloma (MMY1001) - ASCO presentation - June 2017 (Jakubowiak)
PDF
83.7 KB
Safety and efficacy of daratumumab-based regimens in elderly patients with RRMM: Subgroup analysis of POLLUX and CASTOR - ASCO abstract - May 2017 (Mateos)
PDF
150.8 KB
Efficacy of DRd or DVd in RRMM based on cytogenetic risk status - ASCO abstract - May 2017 (Weisel)
PDF
97.0 KB
DVd vs Vd in RRMM: Efficacy and safety update (CASTOR) - ASCO abstract - May 2017 (Lentzsch)
PDF
87.3 KB
Q1 2017 Results Podcast
MP3
22.2 MB
Genmab Q1 2017 Results Presentation
PDF
250.9 KB
Interim Report for the First Quarter 2017
pdf
535.0 KB
Election Results of the Annual General Meeting 2017
PDF
91.4 KB
Scientific Committee Charter
PDF
155.3 KB
AGM 2017 Presentation
PDF
1.4 MB

Page: First Previous
1
2
3
4
5
6
...
18
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Lovpligtig redegørelse for virksomhedsledelse 2011
PDF
129.3 KB
Lovpligtig redegørelse for samfundsansvar 2011
PDF
31.7 KB
Årsrapport 2011
PDF
1.8 MB
Lovpligtig redegørelse for virksomhedsledelse 2010
PDF
131.1 KB
Genmab offentliggør resultat for de første ni måneder af 2011 og opdaterede resultatforventninger til 2011
PDF
287.4 KB
Delårsrapport pr. 30. juni 2011
PDF
286.0 KB
Delårsrapport for 1. kvartal 2011
PDF
278.3 KB
Årsregnskabsmeddelelse 2010
PDF
686.1 KB
Delårsrapport pr. 30. september 2010
PDF
248.7 KB
Delårsrapport pr. 30. juni 2010
PDF
328.8 KB
Delårsrapport for 1. kvartal 2010
PDF
293.7 KB
Årsrapport 2010
PDF
2.5 MB
Årsregnskabsmeddelelse 2009
PDF
688.2 KB
Årsrapport 2009
PDF
2.5 MB
Delårsrapport pr. 30. september 2009
PDF
319.1 KB
Delårsrapport pr. 30. juni 2009
PDF
161.1 KB
Delårsrapport for 1. kvartal 2009
PDF
192.8 KB
Årsregnskabsmeddelelse 2008
PDF
518.9 KB
Årsrapport 2008
PDF
3.7 MB
Kvartalsrapport for perioden 1. januar til 30. september 2008
PDF
181.5 KB
Halvårsrapport pr. 30. juni 2008
PDF
212.3 KB
Kvartalsrapport for 1. kvartal 2008
PDF
263.1 KB
Årsrapport 2007
PDF
2.2 MB
Kvartalsrapport for perioden 1. januar til 30. september 2007
PDF
284.5 KB
Halvårsrapport pr. 30. juni 2007
PDF
274.6 KB
Page: First Previous
1
2
3
4
Next Last